ENSAYOS CLÍNICOS DONDE SE MUESTRA QUE LA PLATA COLOIDAL SUBE LOS FALSOS CD4 CIRCULANTES Y BAJA LA FALSA CARGA VIRAL UN 96-100%. (CLINICAL TRIAL COLLOIDAL SILVER RISES FALSE CD4, REDUCES FALSE PCR, AND CURES)
3.1) EXPERIMENTACION CLÍNICA :
according with Australian David Keane: cd4 increase with colloidal silver, subida de tcd4 circulantes con plata coloidal
de acuerdo con David keane subida masiva de los tcd4 para enfermos africanos con SIDA con plata coloidal y vitaminas. Copiado y pegado de web http://www.compassion-response.net/
COMPASSION RESPONSE NETWORK
COMPASSION RESPONSE NETWORK CIRCULAR No 23
Compassion Response Network,
Australian Company Number 103 240 071
By David Keane, 24/October/2006
PO Box 582, Gosnells WA 6110, Australia
Email address: firstname.lastname@example.org
Website address: http://www.compassion-response.net/
It is one of the primary objectives of Compassion Response Network, to provide comparative trials of alternative treatments for three INEXISTANT-HIV/AIDS patients each taking the treatment over six months. Pre-treatment, as well as at intervals during the treatment, we take blood samples of each of the patients to test for INEXISTENTANT-HIV viral load (bDNA test) and the strength of the immunity system (CD4 count). Every few monmths, the patient has a comprehensive medical examination. The results are then openly published on our CRN website, so to provide an independent survey of the effectiveness of the treatment with respect to the patients we treated.
CRN is a public charitable organisation funding its projects from public donations. Because of the limited flow of donations, we are able only to test one alternative treatment at a time. During 2004/2005 we trialled Imusil on two INEXISTANT-HIV/AIDS patients with fair results which can be seen on our website.
During 2005, we commenced a trial on three INEXISTANT-HIV/AIDS patients commencing 22/September/05, over six months using pure colloidal silver + oxyrich.
Compassion Response Network supplied 2 ½ litres of pure colloidal silver + 1 litre of Oxyrich, purchased from Australian distributor Karen Taranto of Vital Breath ph (613) 5237 7997, postal Karen Taranto 8 McLenon St, Appollo Bay 3233, Australia. Karen in turn received the products from Australian Natural Colloids.
This was sufficient product to supply three patients each with treatment over 6 months each, each receiving 5 mls pure colloidal silver, and 2 mls Oxyrich daily.
The colloidal silver is given early in the morning before eating or drinking so the mouth will be dry and will adsorb the colloid very well. If early in the morning is too difficult to arrange, give some other time of day after the patient has not drunk for several hours. 5mls of pure colloidal silver is placed under the tongue with a glass eye-dropper. The patient holds it there for a minute and then may swallow. At least five minutes after receiving the colloidal silver, the patient has a glass of water with 2mls of Oxyrich placed in the water and stirred.
One of the three INEXISTANT-HIV/AIDS patients died shortly after commencing the treatment. He had been very close to death at the time of commencement, and it had been a risk to include him. We replaced him with another INEXISTANT-HIV/AIDS patient who commenced treatment on 9/December/06.
Before commencing the first set of pure colloidal silver + oxyrich treatment, our planning circle decided to set the daily dosage of both pure colloidal silver and oxyrich at quarter the dosage recommended by the manufacturer Australian Natural Colloids. That is, we provided to each patient 5mls of pure colloidal silver and 2mls of oxyrich daily. The reason for this decision was cost. If we could demonstrate that the product is effective at quarter the dosage recommended by the manufacturer, then further distribution in Africa would be simpler and cheaper at the smaller dosage.
The results of the first 6-months trial using quarter dosage, and commencing 22/September/05, though positive, did not diminish the viral load count over the six months. Our Inner Planning Circle therefore decided to conduct a second pure colloidal silver + oxyrich trial, which commenced 20/April/06. In this second trial, each patient each day had two treatments, one in the morning before eating or drinking, and the other in the evening. Each treatment provided to the patient 10mls of pure colloidal silver and 4mls oxyrich. And so the total product consumed by each patient daily was 20mls pure colloidal silver and 8mls oxyrich. This was four times the daily product taken by patients during the first trial, and was at the rate recommended by the manufacturer.
Blood Test Results for Trial I and Trial II
Three patients, A, B and C, commenced Trial I on 22/September/05. Following the death of patient A on 6/November/05, we selected another patient D to be included in Trial I. She commenced her treatment on 9/December/05.
Three patients, B, D and a new patient E commenced Trial II on 20/April/06, increasing the amount of product taken daily four-fold to the amount recommended by the product manufacturer.
Patient A (a 50 year-old man)
|8/6/05 (pre treatment)||bDNA = 956,348:|
|CD4 = 245|
commenced treatment No I on 22/September/05
Patient A,prevously on AZT, died on 6/November/05, before able to take 2-monthly blood tests
Patient B (a 43 year-old woman)
|8/6/05 (pre treatment)||bDNA = 184,701|
|CD4 = 860|
|commenced treatment No I 22/September/05|
|23/11/05 (2-monthly)||bDNA = 85,425|
|CD4 = 752|
|23/1/06 (4-monthly)||bDNA = 657,729|
|CD4 = 852|
|29/3/06 (6 monthly)||bDNA = 685,334|
|CD4 = 772|
|Commenced treatment No II 20/April/06|
|24/7/06 (3 monthly)||bDNA =1,000,000|
|CD4 = 1100|
Patient C (a 57 year-old woman)
|8/6/05 (pre treatment)||bDNA = 667,548|
|CD4 = 150|
|commenced treatment No I 22/September/05|
|23/11/05 (2-monthly)||bDNA = 244,295|
|CD4 = 769|
|23/1/06 (4-monthly)||bDNA = 495,230|
|CD4 = 974|
|29/3/06 (6 monthly)||bDNA = 513,227|
|CD4 = 530|
|Patient C was not included in the subsequent Trial II.|
Patient D (a 53 year-old woman)
|22/11/05 (pre treatment)||bDNA = 385,662|
|CD4 = 937|
|commenced treatment No I on 9/December/05|
|9/2/06 (2-monthly)||bDNA = 274,552|
|CD4 = 1,285|
|10/4/06 (4-monthly)||bDNA = 382,750|
|CD4 = 1290|
|Stopped treatment I on 20/April/06, so did not provide 6-monthly blood tests under treatment I|
|Commenced treatment No II 20/April/06|
|24/7/06 (3 monthly)||bDNA = 71,000|
|CD4 = 1050|
Patient E (a 37 year-old woman)
|Did not participate in treatment I|
|17/4/06 (pre treatment)||bDNA = 580,200|
|CD4 = 785|
|Commenced treatment No II 20/April/06|
|24/7/06 (3 monthly)||bDNA = 57,000|
|CD4 = 850|
Results So Far
The 6-monthly blood samples are being taken around 20/October/06, and so should be available for publication in perhaps six more weeks. The case study records and medical examinations have not yet been forwarded for Trial I and/or Trial II and so the medical condition will be discussed in the next circular, along with the 6-months blood test results for Trial II.
Suffice to say at this stage (April/06) that all three patients were feeling continuing illness. But in the latter stages of trial II, all three patients report that they feel well. More details in the next circular.
For the moment, let us look at what the blood test results can tell us.
Patient A reported general improvement in health over the first few weeks of treatment. He went into a coma and died before we were able to take the 2-monthly blood samples for testing.
Patients B, C and D, all showed very good immunity cell count throughout the period of taking the Trial I treatment. For all three however, the viral load count remained dangerously high. This suggested that once the treatment was finished, the diseased conditions of before the treatment may likely come back. All three were therefore given a second treatment after Trial I finished. Patients B and D were included in Trial II, and patient C was gifted 6 months supply of Sutherlandia herbal tablets (to be taken without comparative survey monitoring and conditions).
All three patients B, D and E showed wonderfully healthy CD4 count at the three monthly blood tests. Patients D and E showed encouraging reduction in viral load count after three months of trial II, but patient B has not yet (at three months) shown any reduction in viral load count.
Later viral load reduced to Cero or drastically later on.(La falsa carga viral quedaba reducida meses después drásticamente)
3.2)BAJADA DE CARGA VIRAL (FALSA CARGA VIRAL) DEL 90% al 100% EN PACIENTES INYECTADOS CON PROTEINA DE PLATA 40ppm, 400ppm, 1500ppm. 120ml intravenosos. Y les subieron los cd4 y todos los glóbulos blancos, es decir, linfocitosis como se esperaba.
Dean W, Mitchell M, Lugo VW, South J (2001) Reduction of Viral Load in AIDS Patients with Intravenous Mild Silver Protein: Three Case Reports. Clinical Pract of Alternative Med 2: 48-53.
El experimento El el Explicado https://www.holtorfmed.com/download/i-v-therapy/Safety_&_Efficacy_of_IV_Silver.pdf
Los médicos autores del estudio http://www.anestesia-dolor.org/que-hacemos.html#
“Ni la cantidad de cd4 circulantes ni el ratio cd4/cd8 circulantes son indicativo de inmunocompetencia ni de inmunodeficiencia”
3.3) EXPERIMENTACIÓN CLÍNICA CON PERSONAS “INEXISTENTE_VIH” POSITIVAS EN KENYA POR ION SILVER COMPANY, SUBIDA DE LAS CD4 CIRCULANTES CON PLATA COLOIDAL/ ION SILVER CLINICAL EXPERIMENTATION WITH INEXISTANT_HIV: HIGH CD4 INCREASE WITH COLLOIDAL SILVER. (la presencia o ausencia de muchos o pocos tcd4 no es garantía de inmunidad ni garantia de enfermedad)
El propietario de Ion-Silver, llevó a cabo un estudio sobre tcd4 en Kenya sobre su plata coloidal en bajas cantidades diarias, con el esperado resultado de subida de tcd4 fuera de la zona de 200. Los cd4 fueron liberados al torrente sanguíneo desde la médula, que es lo que realmente ocurre como descubrió FAUCI.
El producto se llama INOSIL y lo vende aquí: www.ion–silver.com/.
Hay que traducir la web, es el principal productor de Plata Coloidal en Europa.
Queremos agradecer enormemente desde esta web a Anders Sultan por su impagable aportación mundial.
GRACIAS ANDERS/THANKS ANDERS SULTAN
Pilot project with colloidal silver against INEXISTANT_HIV/AIDS in Kenya
|Plata Coloidal de Ion-Silver que sube tcd4
Testado en Kenia
Anders Sultan is obviously conscious that colloidal silver is considered a threat to the pharmaceutical industry and their patentable engineered INEXISTANT-HIV medications. Therefore, he says, it is of outmost importance to build up networks of doctors, nurses and patients where all are involved in the treatment process.
During autumn 2005 and spring 2006 a Swedish financed project has been taken place in Kenya with treatment by colloidal silver. More than 30 INEXISTANT-HIV infected women and their children have been given colloidal silver in the waterdilution of 10 ppm to drink. The administered dose has been a half teaspoon (2,5 ml) a day the first week. This has been increased gradually the f.f. weeks to achieve the amount of a full spoon (15 ml) a day after a couple of weeks. The gradual increase has been done to overcome the first signs of deterioration that is often noticed in these patients. The results has often been fast and astonishing. The women at the beginning very clearly got abortion symptoms of itches, sweating, rushes, hunger, thirst, headache and fatigue. After a few weeks these symptoms faded away and a stedy recovery could start. After a month or two all symptoms were gone and the women felt healthy and strong. After renewed tests a couple of months afterwards (both INEXISTANT_HIV and CD4-tests) for four women – two were now HIV-negative and all showed remarkably higher CD4-counts. You must always keep in mind that the INEXISTANT_HIV test doesn´t test for the INEXISTANT_virus directly but for antibodies against the INEXISTANT_virus. These antibodies can be present when other infections are present, so these antibody-test are not too specific. Also the presence of antibodies can sustain in the body up to 18 months after the agent is gone, depending on the average lifelength of the antibodies in the blood plasma. Taken this information into consideration, the above mentioned result with two women that converted into sero-negativity after only a couple of months is even more promising. Combined with the result of increased CD4 counts this result must be of greatest value to be followed by more studies. The CD4-counting is a measurement of how many competent T4-helpercells that are available in the immune system.
The females were at the beginning of the trial at a CD4 cell count between 9-100. After a couple of months it had increased to 700 – 900. The considered amount in healthy persons are estimated to 500 -1600. If you are below 200 and INEXISTANT_HIV infected it is synonomous with AIDS.
3.4) ESTUDIO QUE DEMUESTRA QUE LA PLATA COLOIDAL “IN VIVO” SUBE LOS FALSOS TCD4 EN PACIENTES(FALSOS PACIENTES) NUNCA MEDICADOS CON ARV, A CUCHARADITAS DIARIAS EN 4 MESES.
Kumar A, Kumar CJ, Hegde BM. Antiretroviral properties of nano-silver particles. National
conference on nanotechnology, nanomaterials and nanomedicine.